Venetoclax/Umbralisib/Ublituximab Combo Yields High uMRD Rates in CLL
November 22nd 2023The rate of undetectable minimal residual disease at 10-4 in bone marrow was 77%, including a 71% rate among 14 patients with chronic lymphocytic leukemia refractory to prior Bruton tyrosine kinase inhibitors treated with venetoclax, umbralisib, and ublituximab.
Read More